Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
144 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Review, H2 2016', provides in depth analysis on Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information on the Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - The report reviews Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects - The report assesses Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Overview 8 Therapeutics Development 9 Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Stage of Development 9 Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Therapy Area 10 Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Indication 11 Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Products Glance 13 Late Stage Products 13 Early Stage Products 14 Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Companies 15 Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Universities/Institutes 23 Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Therapeutics Assessment 25 Assessment by Monotherapy/Combination Products 25 Assessment by Mechanism of Action 26 Assessment by Route of Administration 27 Assessment by Molecule Type 28 Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Companies Involved in Therapeutics Development 30 AbbVie Inc 30 ACEA Biosciences, Inc. 32 Advinus Therapeutics Ltd 33 ArQule, Inc. 34 BeiGene, Ltd. 35 Beijing Hanmi Pharmaceutical Co Ltd 36 Biogen Inc 37 Bristol-Myers Squibb Company 38 Celgene Corporation 39 CrystalGenomics, Inc. 40 Genentech, Inc. 41 Hanmi Pharmaceuticals, Co. Ltd. 42 LSK BioPartners, Inc. 43 Merck KGaA 44 Ono Pharmaceutical Co., Ltd. 45 Pharmacyclics, Inc. 46 Principia Biopharma Inc. 47 Redx Pharma Plc 48 Simcere Pharmaceutical Group 49 Sunesis Pharmaceuticals, Inc. 50 Takeda Pharmaceutical Company Limited 51 Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Drug Profiles 52 ABBV-599 - Drug Profile 52 AC-058 - Drug Profile 53 acalabrutinib - Drug Profile 54 Antisense Oligonucleotides to Activate BTK for X-linked Agammaglobulinemia - Drug Profile 57 ARQ-531 - Drug Profile 58 BGB-3111 - Drug Profile 59 BIIB-068 - Drug Profile 62 BMS-986142 - Drug Profile 63 BMS-986195 - Drug Profile 64 CG-026806 - Drug Profile 65 CG-036806 - Drug Profile 66 Drug to Inhibit BTK for Undisclosed Indications - Drug Profile 67 DTRMWXHS-12 - Drug Profile 68 EBI-1266 - Drug Profile 69 EBI-1367 - Drug Profile 70 HCI-1401 - Drug Profile 71 HCI-1684 - Drug Profile 72 HM-71224 - Drug Profile 73 ibrutinib - Drug Profile 74 M-2951 - Drug Profile 97 M-7583 - Drug Profile 98 ONO-4059 - Drug Profile 99 PLS-123 - Drug Profile 101 PNQ-154 - Drug Profile 102 PNQ-849 - Drug Profile 103 PRN-1008 - Drug Profile 104 PRN-473 - Drug Profile 106 RDX-002 - Drug Profile 107 RG-7845 - Drug Profile 108 Small Molecule to Inhibit Bruton's Tyrosine Kinase for Arthritis - Drug Profile 109 Small Molecule to Inhibit BTK and IRAK4 for Autoimmune Disorders and Rheumatoid Arthritis - Drug Profile 110 Small Molecule to Inhibit BTK for Immunology - Drug Profile 111 Small Molecule to Inhibit BTK for Inflammation, Autoimmune Disorders and Cancer - Drug Profile 112 Small Molecule to Inhibit BTK for Oncology - Drug Profile 113 Small Molecule to Target BTK for Immunology - Drug Profile 114 Small Molecules to Inhibit BTK for Oncology - Drug Profile 115 Small Molecules to Inhibit BTK for Rheumatoid Arthritis - Drug Profile 116 SNS-062 - Drug Profile 118 spebrutinib besylate - Drug Profile 120 TAK-020 - Drug Profile 122 X-022 - Drug Profile 123 Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Dormant Projects 124 Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Discontinued Products 127 Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Featured News & Press Releases 128 Appendix 140 Methodology 140 Coverage 140 Secondary Research 140 Primary Research 140 Expert Panel Validation 140 Contact Us 140 Disclaimer 141
List of Tables
Number of Products under Development for, H2 2016 12 Number of Products under Development by Therapy Area, H2 2016 13 Number of Products under Development by Indication, H2 2016 14 Comparative Analysis by Late Stage Development, H2 2016 16 Comparative Analysis by Early Stage Products, H2 2016 17 Number of Products under Development by Companies, H2 2016 18 Products under Development by Companies, H2 2016 19 Products under Development by Companies, H2 2016 (Contd..1) 20 Products under Development by Companies, H2 2016 (Contd..2) 21 Products under Development by Companies, H2 2016 (Contd..3) 22 Products under Development by Companies, H2 2016 (Contd..4) 23 Products under Development by Companies, H2 2016 (Contd..5) 24 Products under Development by Companies, H2 2016 (Contd..6) 25 Number of Products under Investigation by Universities/Institutes, H2 2016 26 Products under Investigation by Universities/Institutes, H2 2016 27 Assessment by Monotherapy/Combination Products, H2 2016 28 Number of Products by Stage and Mechanism of Action, H2 2016 29 Number of Products by Stage and Route of Administration, H2 2016 30 Number of Products by Stage and Molecule Type, H2 2016 32 Pipeline by AbbVie Inc, H2 2016 34 Pipeline by ACEA Biosciences, Inc., H2 2016 35 Pipeline by Advinus Therapeutics Ltd, H2 2016 36 Pipeline by ArQule, Inc., H2 2016 37 Pipeline by BeiGene, Ltd., H2 2016 38 Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2016 39 Pipeline by Biogen Inc, H2 2016 40 Pipeline by Bristol-Myers Squibb Company, H2 2016 41 Pipeline by Celgene Corporation, H2 2016 42 Pipeline by CrystalGenomics, Inc., H2 2016 43 Pipeline by Genentech, Inc., H2 2016 44 Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 45 Pipeline by LSK BioPartners, Inc., H2 2016 46 Pipeline by Merck KGaA, H2 2016 47 Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 48 Pipeline by Pharmacyclics, Inc., H2 2016 49 Pipeline by Principia Biopharma Inc., H2 2016 50 Pipeline by Redx Pharma Plc, H2 2016 51 Pipeline by Simcere Pharmaceutical Group, H2 2016 52 Pipeline by Sunesis Pharmaceuticals, Inc., H2 2016 53 Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 54 Dormant Projects, H2 2016 127 Dormant Projects (Contd..1), H2 2016 128 Dormant Projects (Contd..2), H2 2016 129 Discontinued Products, H2 2016 130
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
